Key result
Intravenous TY-51924 administered before reperfusion reduced infarct size by up to 52.4% compared to vehicle in a canine model of ischemia/reperfusion injury.
Why the study?
Does TY-51924 reduce infarct size in anesthetized dogs subjected to ischemia/reperfusion injury?
Does TY-51924 reduce infarct size in anesthetized dogs subjected to ischemia/reperfusion injury?
TY-51924 reduces infarct size in a canine model of ischemia/reperfusion injury when administered before reperfusion.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for TY-51924 in ischemia/reperfusion injury; human trials needed before clinical consideration.
The inhibitory effects of sodium 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ylmethyl sulfate monoethanolate (TY-51924) are selective for Na(+)/H(+) exchanger (NHE)-1 in PS120 cells expressing human NHE isoforms assayed by NH(4)Cl prepulse technique. The median inhibitory concentrations (micromolar) of TY-51924 were 0.095 ± 0.008 (NHE-1), 0.621 ± 0.093 (NHE-2), and >100 (NHE-3). In anesthetized dogs subjected to 90 minutes ischemia/300 minutes reperfusion, intravenous bolus TY-51924 at 5 and 10 mg/kg administered 5 minutes before reperfusion reduced infarct size. The infarct size reduction ratios of TY-51924 at 5 and 10 mg/kg versus vehicle were 32.8% and 52.4%, respectively. But TY-51924 at 10 mg/kg administered 10 minutes after reperfusion did not reduce infarct size. In 2-step intravenous infusion initiated 15 minutes before reperfusion, TY-51924 at low dose (3.8 mg/kg per 5 minutes, then 6.2 mg/kg per 20 minutes) and at high dose (7.6 mg/kg per 5 minutes, then 12.4 mg/kg per 20 minutes) reduced infarct size. The infarct size reduction ratios of TY-51924 at 10 and 20 mg/kg versus vehicle were 39.2% and 51.7%, respectively; plasma drug concentrations at reperfusion were 16.8 and 38.8 μg/mL, respectively. This indicates that maintaining a plasma drug concentration of >20 μg/mL at reperfusion enables TY-51924 to reduce infarct size by inhibiting the NHE, which is activated during the early period of reperfusion.
No takes yet. Share an insight, caveat, or question.
Sasamori et al. (2013) studied Ischemia/reperfusion injury. TY-51924 vs. Vehicle was evaluated on Infarct size reduction ratio. Intravenous TY-51924 administered before reperfusion reduced infarct size by up to 52.4% compared to vehicle in a canine model of ischemia/reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: